Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Franziska Michalski, Sebastian Werth, MD, Christina Köhler, MD, Luise Tittl, Katharina Daschkow, Jan Beyer-Westendorf, MD

Blood (2014) 124 (21): 2876.

https://doi.org/10.1182/blood.V124.21.2876.2876

Published: 2014

Journal Articles

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Jan Beyer-Westendorf, MD, Franziska Michalski, Sebastian Werth, MD, Luise Tittl, Christina Köhler, MD, Norbert Weiss, Prof.

Blood (2014) 124 (21): 1538.

https://doi.org/10.1182/blood.V124.21.1538.1538

Published: 2014

Journal Articles

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Franziska Ebertz, Sebastian Werth, MD, Christina Köhler, MD, Franziska Michalski, Ulrike Hänsel, Luise Tittl, Katharina Daschkow, Thomas Schreier, Jan Beyer-Westendorf, MD

Blood (2014) 124 (21): 1541.

https://doi.org/10.1182/blood.V124.21.1541.1541

Published: 2014

Journal Articles

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Christina Köhler, MD, Sebastian Werth, MD, Luise Tittl, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 2380.

https://doi.org/10.1182/blood.V122.21.2380.2380

Published: 2013

Journal Articles

Changes Of Coagulation Activation Parameters After Discontinuation Of VTE Treatment With Vitamin-K Antagonists, Apixaban, Rivaroxaban Or Dabigatran and Impact On Clinical Outcome After 12 Months

Sebastian Werth, MD, Christina Köhler, MD, Siegmund Gehrisch, Thoralf Stange, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 3647.

https://doi.org/10.1182/blood.V122.21.3647.3647

Published: 2013

Journal Articles

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

Kati Förster, Franziska Ebertz, Vera Gelbricht, Denise Röllig, Luise Tittl, Christina Köhler, MD, Sebastian Werth, MD, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 214.

https://doi.org/10.1182/blood.V122.21.214.214

Published: 2013

NARROW

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Changes Of Coagulation Activation Parameters After Discontinuation Of VTE Treatment With Vitamin-K Antagonists, Apixaban, Rivaroxaban Or Dabigatran and Impact On Clinical Outcome After 12 Months

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

Email alerts

ASH Publications

American Society of Hematology

Centrally Adjudicated Cause of Death during Noac Treatment – Results of the Prospective Dresden Noac Registry (NCT01588119)

Characteristics of Atrial Fibrillation Patients Not Switched from Vka to Noac and Persistence on Vka – a Subgroup Analysis of the Prospective Dresden Noac Registry (NCT01588119)

Real Life Efficacy and Safety of Dabigatran for Stroke Prevention in Atrial Fibrillation – Final Results of the Prospective Noac Registry (NCT01588119)

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Changes Of Coagulation Activation Parameters After Discontinuation Of VTE Treatment With Vitamin-K Antagonists, Apixaban, Rivaroxaban Or Dabigatran and Impact On Clinical Outcome After 12 Months

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only